Related Experiment Video
Updated: May 24, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.5K
NLRP3 inflammasomes pathway: a key target for Metformin
Yasamin Hosseini1,2, Amirhossein Niknejad1,2, Ayeh Sabbagh Kashani1,2
1Faculty of Pharmacy, Department of Toxicology and Pharmacology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Inflammopharmacology
|March 5, 2025
Summary
Metformin (MET), an anti-diabetic drug, shows potential anti-inflammatory effects by modulating the Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing 3 (NLRP3) inflammasome pathway, suggesting therapeutic utility for inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- The Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing 3 (NLRP3) inflammasome is a key regulator of inflammatory responses, implicated in numerous diseases.
- NLRP3 activation is triggered by cellular damage and oxidative stress, leading to the release of pro-inflammatory cytokines.
- Metformin (MET), a widely used anti-diabetic drug, possesses known anti-inflammatory properties.
Purpose of the Study:
- To review existing evidence on the impact of Metformin on the NLRP3 inflammasome pathway.
- To evaluate Metformin's potential therapeutic utility in diseases associated with NLRP3 activation.
Main Methods:
- Literature review of studies investigating Metformin's effects on NLRP3 inflammasome components and activity.
- Analysis of preclinical and clinical data regarding Metformin's anti-inflammatory mechanisms.
Main Results:
- Metformin demonstrates inhibitory effects on NLRP3 inflammasome activation through various mechanisms.
- Evidence suggests Metformin can mitigate NLRP3-driven inflammation, offering a potential therapeutic strategy.
Conclusions:
- Metformin's modulation of the NLRP3 pathway supports its consideration for treating inflammatory conditions.
- Further research is warranted to fully elucidate Metformin's role and optimize its use in NLRP3-mediated diseases.
More Related Videos
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:24Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
01:28Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
01:31Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K